View Future GrowthOncotelic Therapeutics 과거 순이익 실적과거 기준 점검 3/6Oncotelic Therapeutics은 연평균 72.6%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 30%의 비율로 증가했습니다. 매출은 연평균 93.4%의 비율로 감소했습니다.핵심 정보72.62%순이익 성장률75.63%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률-93.39%자기자본이익률95.15%순이익률n/a최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesOncotelic Therapeutics, Inc. announced delayed annual 10-K filingApr 01Oncotelic Therapeutics, Inc.'s Sapu Nano Launches Deciparticle Platform and Presents Clinical PipelineMar 25Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic CancerDec 16Oncotelic and Sapu Nano Announce Deciparticle Led Biomarker Framework Identifying Tumors Most Likely to Respons to Iv Sapu003, an Intravenous Everolimus NanomedicineDec 04+ 1 more updateOncotelic and Sapu Nano Unveils Broad-Appointment of Broad-Appointment of Sapu Nano Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide DrugsDec 03Oncotelic Therapeutics, Inc. announced delayed 10-Q filingNov 15Sapu Nano Unveils First-In-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research SymposiumOct 10Sapu Nano's Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bio Availability for Breast Cancer PatientsSep 24Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage PipelineSep 13Oncotelic Therapeutics, Inc. Provides Update on Its Clinical PipelineSep 05Oncotelic Therapeutics, Inc. Highlights Peer-Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer PatientsJul 17Oncotelic Therapeutics, Inc. Announces Publication of Landmark Study on TGFB2 Gene Methylation as A Positive Prognostic Marker in Pancreatic CancerJun 25Oncotelic Therapeutics, Inc. announced delayed annual 10-K filingApr 01Oncotelic Therapeutics, Inc. Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2Mar 25Oncotelic Therapeutics, Inc. Implements PDAOAI PlatformJan 01Oncotelic Therapeutics, Inc. announced delayed 10-Q filingNov 15Oncotelic Therapeutics, Inc. announced delayed annual 10-K filingApr 02Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas PatientsMar 27Oncotelic Therapeutics, Inc. announced delayed 10-Q filingAug 17Oncotelic Therapeutics, Inc. announced delayed 10-Q filingMay 16Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell CancerFeb 07Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic CancerJan 26Oncotelic Therapeutics, Inc. Presents Clinical Data of Confirming TGF-BETA>2 as the Appropriate Target for Gliomas At JCA-AACR Meeting 2022Dec 20Oncotelic Therapeutics, Inc. announced delayed 10-Q filingNov 15Oncotelic Initiates Clinical Trials Evaluating OT-101 Against Pediatric GliomasNov 09Oncotelic Therapeutics, Inc. announced delayed 10-Q filingAug 16Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)May 26Oncotelic Therapeutics, Inc. announced delayed 10-Q filingMay 17Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory OfficerMay 05Oncotelic Therapeutics, Inc. Appoints Fatih Uckun as Chief Medical OfficerMay 04Oncotelic Therapeutics, Inc. announced delayed annual 10-K filingApr 01Oncotelic Presenting OT-101 Oncology Program at Biotechgate Digital PartneringJan 20Oncotelic Therapeutics, Inc. Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for MelanomaJan 07Oncotelic Announces ORF8 Mutations are Driving the Evolution of the Delta and the Omicron VariantsDec 23Oncotelic Therapeutics, Inc. announced that it has received $0.5 million in funding from Talos Victory Fund, LLC, Mast Hill Fund, L.P.Dec 02+ 1 more updateOncotelic Announces Positive Topline Data for OT-101 C001 COVID StudyNov 24Oncotelic Therapeutics, Inc. Reports PulmoHealTM/ ArtiVedaTM Proven Active against Mild and Moderate COVID-19 Following the Preplanned Prospective Analysis of ARTI-19 Clinical TrialAug 25Oncotelic Therapeutics, Inc. announced delayed 10-Q filingAug 17Oncotelic Therapeutics, Inc. announced that it has received $0.6985 million in funding from Autotelic Inc.Aug 06Oncotelic Therapeutics, Inc. Closes Covid-19 Clinical Trial EarlyJun 16Oncotelic Therapeutics, Inc. announced delayed 10-Q filingMay 18Oncotelic Therapeutics, Inc. announced delayed annual 10-K filingApr 03Mateon Announces Initiation of Phase 1B Clinical Trial on OT-101/IL-2 Combination Therapy for Solid TumorsMar 16Mateon Therapeutics, Inc. Announces Enrollment Enrollment of its Sentinel Part 1 and Part 2 COVID-19Mar 10Mateon Therapeutics, Inc. and Windlas Biotech Limited Launches Pulmoheal™, A Combined Lung Therapy and Ai Telemedicine 360° SolutionFeb 23Mateon Therapeutics, Inc. Partners with The Chopra Foundation for Development of PulmoHea and ARTIVedaFeb 18Mateon Therapeutics, Inc. Announces Completion of Arti-19 and Publication of Positive Interim DataFeb 04Mateon Therapeutics, Inc. Launches its Artificial Intelligence Telemedicine Platform for Post Marketing Survey to Support the Launch of its Drug Product, PulmoHealTMFeb 02Mateon Announces Positive Interim Results from ARTI-19 Clinical Trial Evaluating Covid-19 TherapeuticJan 14Mateon Therapeutics and Windlas Biotech Enter into Definitive Agreement to Commercialze Artiveda™ Against Covid-19Nov 12Mateon Therapeutics, Inc. Announces the Receipt of Approval from Instituto Nacional De Salud (Ins), the Regulatory Agency of Peru, to Initiate the Company’s C001- Phase 2 Clinical Trial of OT-101Nov 06Mateon Therapeutics, Inc. Receives Approval from Republica Argentina for Phase 2 Global Study for OT-101Oct 20Mateon Therapeutics, Inc. Announces First Patient Enrolled in ARTI-19: A Multicenter Interventional Study of ArtiShield Against COVID-19Oct 08Mateon Therapeutics, Inc. and Windlas Biotech Limited Announce ArtiShield Is Now Approved for Manufacture and Marketing by the Ministry of AYUSHOct 06Mateon Therapeutics, Inc. announced that it has received $2 million in fundingJun 30매출 및 비용 세부 내역Oncotelic Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:OTLC 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2502493030 Sep 250-21030 Jun 250-40031 Mar 250-40031 Dec 240-50030 Sep 240-50030 Jun 240-10031 Mar 240-81031 Dec 230-81030 Sep 230-121030 Jun 230-131031 Mar 23091031 Dec 22055130 Sep 22095130 Jun 22086231 Mar 220-119331 Dec 210-95430 Sep 210-115630 Jun 210-115631 Mar 211-83631 Dec 202-105430 Sep 202-105230 Jun 202-95131 Mar 200-105131 Dec 190-73130 Sep 190-32130 Jun 190-31131 Mar 190-21131 Dec 180-101양질의 수익: OTLC의 비현금 수익 수준이 높습니다.이익 마진 증가: OTLC는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: OTLC는 지난 5년 동안 흑자전환하며 연평균 72.6%의 수익 성장을 기록했습니다.성장 가속화: OTLC는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: OTLC는 지난해 흑자전환하여 지난 해 수익 성장률을 Biotechs 업계(40.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: OTLC의 자본 수익률(95.1%)은 뛰어남으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/03 00:32종가2026/05/01 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Oncotelic Therapeutics, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Theodore O'NeillLitchfield Hills Research, LLC
Oncotelic Therapeutics, Inc.'s Sapu Nano Launches Deciparticle Platform and Presents Clinical PipelineMar 25
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic CancerDec 16
Oncotelic and Sapu Nano Announce Deciparticle Led Biomarker Framework Identifying Tumors Most Likely to Respons to Iv Sapu003, an Intravenous Everolimus NanomedicineDec 04+ 1 more update
Oncotelic and Sapu Nano Unveils Broad-Appointment of Broad-Appointment of Sapu Nano Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide DrugsDec 03
Sapu Nano Unveils First-In-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research SymposiumOct 10
Sapu Nano's Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bio Availability for Breast Cancer PatientsSep 24
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage PipelineSep 13
Oncotelic Therapeutics, Inc. Highlights Peer-Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer PatientsJul 17
Oncotelic Therapeutics, Inc. Announces Publication of Landmark Study on TGFB2 Gene Methylation as A Positive Prognostic Marker in Pancreatic CancerJun 25
Oncotelic Therapeutics, Inc. Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2Mar 25
Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic CancerJan 26
Oncotelic Therapeutics, Inc. Presents Clinical Data of Confirming TGF-BETA>2 as the Appropriate Target for Gliomas At JCA-AACR Meeting 2022Dec 20
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)May 26
Oncotelic Therapeutics, Inc. Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for MelanomaJan 07
Oncotelic Announces ORF8 Mutations are Driving the Evolution of the Delta and the Omicron VariantsDec 23
Oncotelic Therapeutics, Inc. announced that it has received $0.5 million in funding from Talos Victory Fund, LLC, Mast Hill Fund, L.P.Dec 02+ 1 more update
Oncotelic Therapeutics, Inc. Reports PulmoHealTM/ ArtiVedaTM Proven Active against Mild and Moderate COVID-19 Following the Preplanned Prospective Analysis of ARTI-19 Clinical TrialAug 25
Oncotelic Therapeutics, Inc. announced that it has received $0.6985 million in funding from Autotelic Inc.Aug 06
Mateon Announces Initiation of Phase 1B Clinical Trial on OT-101/IL-2 Combination Therapy for Solid TumorsMar 16
Mateon Therapeutics, Inc. Announces Enrollment Enrollment of its Sentinel Part 1 and Part 2 COVID-19Mar 10
Mateon Therapeutics, Inc. and Windlas Biotech Limited Launches Pulmoheal™, A Combined Lung Therapy and Ai Telemedicine 360° SolutionFeb 23
Mateon Therapeutics, Inc. Partners with The Chopra Foundation for Development of PulmoHea and ARTIVedaFeb 18
Mateon Therapeutics, Inc. Announces Completion of Arti-19 and Publication of Positive Interim DataFeb 04
Mateon Therapeutics, Inc. Launches its Artificial Intelligence Telemedicine Platform for Post Marketing Survey to Support the Launch of its Drug Product, PulmoHealTMFeb 02
Mateon Announces Positive Interim Results from ARTI-19 Clinical Trial Evaluating Covid-19 TherapeuticJan 14
Mateon Therapeutics and Windlas Biotech Enter into Definitive Agreement to Commercialze Artiveda™ Against Covid-19Nov 12
Mateon Therapeutics, Inc. Announces the Receipt of Approval from Instituto Nacional De Salud (Ins), the Regulatory Agency of Peru, to Initiate the Company’s C001- Phase 2 Clinical Trial of OT-101Nov 06
Mateon Therapeutics, Inc. Receives Approval from Republica Argentina for Phase 2 Global Study for OT-101Oct 20
Mateon Therapeutics, Inc. Announces First Patient Enrolled in ARTI-19: A Multicenter Interventional Study of ArtiShield Against COVID-19Oct 08
Mateon Therapeutics, Inc. and Windlas Biotech Limited Announce ArtiShield Is Now Approved for Manufacture and Marketing by the Ministry of AYUSHOct 06